Category: Select Oncology Journal Articles

Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety...

Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of...

Background Squamous non-small cell lung cancer (SQ-NSCLC) is the 2nd most common type of lung cancer. Given the paucity of actionable oncogene drivers, and lack of efficacy from multiple therapies in the Lung-MAP trial, there is...

Background Immunocytokines can strengthen anti-PD-(L)1 therapy by promoting T-cell survival, but their shortened half-life and systemic toxicity limit their clinical development. We developed a bifunctional anti-PD-1/IL7v...

Background Several groups, including ours, have shown CD39 to be a tumor-specific CD8+ T cell marker. In non-small cell lung cancer (NSCLC) and colorectal carcinoma (CRC), CD8+ T cells lacking CD39 expression are bystander tumor...

Background Predictive models applied to digital pathology images show promise for the rapid and objective analysis of patient samples to identify features of the tumor microenvironment (TME) predictive of treatment response....

Background Advancement in multiplex immunohistochemistry (mIHC) allows for single-cell tumor microenvironment analysis, greatly enhancing our comprehension of cancer immunology.1 However, clinical application of mIHC remains...

Background Spatial transcriptomics (ST) has greatly advanced gene biomarker discovery1 and understanding of intra-tumoral heterogeneity.2 Deep learning methods applied to H&E images have improved clinical trials,3 inspiring...

Background From 2019–2022, we prospectively enrolled 1200 pan-cancer patients treated with immune checkpoint inhibitors (CPI) and identified three CPI-diabetes mellitus (DM) cases as part of the Radiohead study.1 Baseline...

Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using...

Background Tumor-infiltrating lymphocytes (TILs) serve as both prognostic and predictive biomarker in triple-negative breast cancer (TNBC). TNBC exhibits six distinct molecular subtypes —basal-like 1, basal-like 2,...